Zyrtec Articles
Belgium’s UCB posts disappointing 2009 results, but projects better future based on newer drugs
3 March 2010
UCB revenue falls on drop in US sales
1 May 2009
UCB absorbs Zyrtec patent expiry, but 2008 profit still down 74% on restructuring charges
9 March 2009
Pfizer's 3rd-qtr 2008 profit triples due to Exubera write-off; revenues flat at $12B
27 October 2008
UCB to cut 17% of staff in major restructuring
8 September 2008
Taro gains final FDA appro for cetirizine
30 June 2008
UCB report is cagey about interim results
26 May 2008
Rx-to-OTC switching making comeback
21 April 2008
UCB drops 12% on Neupro batches recall
31 March 2008
Final FDA OK for generic OTC cetirizine
7 January 2008
UCB raises guidance for 2008 above consensus
24 December 2007
US FDA approves new formulations of Zyrtec
26 November 2007
FDA OKs non-Rx sale of allergy drug Zyrtec
26 November 2007
Japanese generic drug listings for November
21 November 2007
US FDA clears J&J's non-Rx Zyrtec
19 November 2007
UCB's 1st-half profits fall 39% on Schwarz buy
6 August 2007
Caraco gets tentative OK for generic Zyrtec from FDA
11 June 2007
Beximco starts selling generics to Ghana
9 April 2007
Ranbaxy gets tentative approval for cetirizine syrup
13 November 2006
UCB 1st-half results ahead of forecasts
7 August 2006
Japan stock market week to July 17, 2006
24 July 2006
J&J wins bidding war for Pfizer
3 July 2006
Globalpharma and Ethypharm sign cetirizine deal
3 April 2006
UCB sees 2005 income grow to 270M euros
20 March 2006
UCB projects income of 260 M euros for 2005
19 December 2005
Better-than-expected 1st qtr for Daiichi
22 August 2005
Stock Commentary - Tokyo
15 August 2005
Japan stock market week to August 8
15 August 2005
UCB 1st-half net profits leap 232%
8 August 2005
UCB confirms strong US sales of Zyrtec
25 July 2005
GSK to distribute Zyrtec in Japan
25 April 2005
Celltech boosts UCB 2004 results
14 February 2005
UCB confirms Zyrtec sales performance
24 January 2005
Stock Commentary - New York
6 September 2004
Indian drug price study sees large trade margins
2 August 2004
Stock Commentary - Europe
26 April 2004
Keppra sales data and Pfizer rumors boost UCB
19 April 2004
New chewable Zyrtec cleared by FDA
29 March 2004
Stock Commentary - Europe
3 November 2003
Stock Commentary - Europe
23 June 2003
US FDA "has authority for Rx-OTC switches"
5 May 2003
California directs HMOs over switched drugs
7 April 2003
Stock Commentary - Europe
10 March 2003
Zyrtec continues to drive UCB pharma
17 February 2003
Finland's Oriola takes over new drug distribution role
27 January 2003
UCB profits up 14% in 2nd quarter
12 August 2002
10 most effective US DTC television ads
5 August 2002
UCB starts trials of novel asthma compound
22 July 2002
Stock Commentary - Europe
29 April 2002
Pfizer 1st-qtr EPS increases 18%
22 April 2002
Profits on the increase at Belgium's UCB Group
15 April 2002
Stock Commentary - Europe
18 March 2002
UCB not threatened by Claritin's OTC version
18 March 2002
Zyrtec driving sales and earnings at UCB
18 February 2002
US HHS Sec backs "some" OTC switches
18 February 2002
UCB to post 20% profit growth in 2001
12 December 2001
UCB's Xyzal cleared for marketing in EU
31 August 2001
Pfizer's Zyrtec-D 12-Hour approved in USA
16 August 2001
Update: UCB 1st-half pharma turnover leaps 31%
31 July 2001
UCB 1st-half pharma sales leap 31%
30 July 2001
UCB 1st-half pharma sales leap 31%
27 July 2001
Update - Pfizer second-quarter net income leaps 31%
18 July 2001
UK MCA seeks GSL switch for eight drugs
5 July 2001
US FDA discusses third-party OTC switch call
25 June 2001
Good start to 2001 for UCB pharma
15 June 2001
Unprecedented US Rx-OTC switch request
1 May 2001
UCB profits up 23% in 2000
11 April 2001
New world market forecasts from DR
6 April 2001
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
